Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
相关临床试验
30
27 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
27
90.0%
已完成
1
3.3%
招募中
2
6.7%
暂无批准数据
- Inventiva appointed Chris Benecchi as Chief Operating Officer to lead operational readiness ahead of the NATiV3 Phase 3 topline results for lanifibranor in MASH, expected in Q4 2026. - Mr. Benecchi brings 30 years of biopharmaceutical leadership experience, most recently serving as CEO of Motric Bio, with prior launch roles at Sage Therapeutics, UCB, and Alexion. - Inventiva anticipates a potential U.S. launch of lanifibranor, subject to regulatory approval, in 2028, and is building commercial capabilities to support it. - Lanifibranor is a novel pan-PPAR agonist under investigation for metabolic dysfunction-associated steatohepatitis (MASH) and has not been approved by any regulatory authority.
- Andera Partners, managing over $6 billion, uses a stage-diversified single-fund model spanning early-stage creation (20%), mid-stage Series B to phase one (50%), and late-stage public-market plays (30%). - Litzka argues biotech companies fail more often from "bad reasons" — operational, regulatory, and communication breakdowns — than from bad science, and boards must help companies "fail for the good reasons." - The Tupolis ADC pivot exemplifies the philosophy: the Munich company shifted from a weak clinical program to its versatile linker technology and was acquired by Gilead in 2026. - Litzka offers a measured view of AI as a productivity tool in patient preselection and compound selection, while warning that China's fast-moving ADC machinery poses a serious competitive threat.
- The global NASH treatment market is projected to grow from USD 8.75 billion in 2025 to USD 46.87 billion by 2032, expanding at a CAGR of 27.1%. - Madrigal's Rezdiffra, approved in March 2024, created the first dedicated liver-directed prescription pathway for noncirrhotic NASH with moderate-to-advanced fibrosis. - Novo Nordisk's Wegovy gained FDA approval in August 2025 for MASH with F2–F3 fibrosis, connecting liver treatment to established obesity and diabetes care networks. - Late-stage pipeline candidates from Eli Lilly, Akero Therapeutics, 89bio, Inventiva, and Boehringer Ingelheim could create a multi-mechanism, segmented treatment market.
- Claret Capital Partners has invested €43 million as part of Inventiva's €130 million debt financing to support late-stage clinical development of lanifibranor. - Lanifibranor is an oral once-daily pan-PPAR agonist currently in the Phase 3 NATiV3 trial for MASH, with top-line results expected in Q4 2026. - MASH affects an estimated 20–25% of patients with fatty liver disease globally and is projected to become the leading cause of liver transplants for women in the US. - The financing, provided alongside BlackRock-managed funds, positions Inventiva for anticipated clinical and regulatory milestones in 2026 and 2027.
